[go: up one dir, main page]

HK1103928A1 - 2-oxy-4h-3,1-benzoxazin-4-ones for treatment of obesity - Google Patents

2-oxy-4h-3,1-benzoxazin-4-ones for treatment of obesity Download PDF

Info

Publication number
HK1103928A1
HK1103928A1 HK07108198.6A HK07108198A HK1103928A1 HK 1103928 A1 HK1103928 A1 HK 1103928A1 HK 07108198 A HK07108198 A HK 07108198A HK 1103928 A1 HK1103928 A1 HK 1103928A1
Authority
HK
Hong Kong
Prior art keywords
benzoxazine
methyl
compound
formula
alkyl
Prior art date
Application number
HK07108198.6A
Other languages
English (en)
Chinese (zh)
Other versions
HK1103928B (en
Inventor
H.F.胡德森
R.唐恩哈姆
T.J.米歇尔
B.J.卡尔
C.R.敦克
R.M.J.帕尔默
Original Assignee
罗吉尼有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900413.7A external-priority patent/GB9900413D0/en
Priority claimed from GBGB9917294.2A external-priority patent/GB9917294D0/en
Application filed by 罗吉尼有限责任公司 filed Critical 罗吉尼有限责任公司
Publication of HK1103928A1 publication Critical patent/HK1103928A1/xx
Publication of HK1103928B publication Critical patent/HK1103928B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/241,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26Two oxygen atoms, e.g. isatoic anhydride
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK07108198.6A 1999-01-08 2007-07-27 2-oxy-4h-3,1-benzoxazin-4-ones for treatment of obesity HK1103928B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9900413.7 1999-01-08
GBGB9900413.7A GB9900413D0 (en) 1999-01-08 1999-01-08 Inhibitors
GBGB9917294.2A GB9917294D0 (en) 1999-07-22 1999-07-22 Inhibitors
GB9917294.2 1999-07-22

Publications (2)

Publication Number Publication Date
HK1103928A1 true HK1103928A1 (en) 2007-12-28
HK1103928B HK1103928B (en) 2012-05-18

Family

ID=

Also Published As

Publication number Publication date
US7825113B2 (en) 2010-11-02
NO20013381L (no) 2001-09-07
RU2245331C2 (ru) 2005-01-27
US20080161301A1 (en) 2008-07-03
US20030195206A1 (en) 2003-10-16
CN1315813C (zh) 2007-05-16
MY122578A (en) 2006-04-29
CN1359378A (zh) 2002-07-17
US8877750B2 (en) 2014-11-04
CA2359819C (en) 2008-08-12
NO333922B1 (no) 2013-10-21
KR20020000542A (ko) 2002-01-05
EP1143977B3 (en) 2012-10-24
PL207383B1 (pl) 2010-12-31
AU1884600A (en) 2000-07-24
US7858617B2 (en) 2010-12-28
HK1047588B (zh) 2007-08-24
EP1143977B1 (en) 2005-04-20
KR100678998B1 (ko) 2007-02-07
CN1915981B (zh) 2011-09-28
CA2359819A1 (en) 2000-07-13
DE60019555D1 (de) 2005-05-25
US20110065697A1 (en) 2011-03-17
MXPA01006921A (es) 2003-06-04
JP3822439B2 (ja) 2006-09-20
AU765147B2 (en) 2003-09-11
HUP0105003A2 (en) 2002-06-29
DE60019555T2 (de) 2006-02-23
HK1047588A1 (en) 2003-04-24
ES2240052T3 (es) 2005-10-16
NO20013381D0 (no) 2001-07-06
DK1143977T3 (da) 2005-08-15
NZ512740A (en) 2003-10-31
WO2000040247A1 (en) 2000-07-13
HUP0105003A3 (en) 2004-11-29
AU765147C (en) 2007-05-31
ES2240052T7 (es) 2013-02-14
CH1143977H1 (fr) 2007-02-15
SI1143977T1 (xx) 2005-08-31
EP1143977A1 (en) 2001-10-17
AR022204A1 (es) 2002-09-04
PT1143977E (pt) 2005-08-31
US6624161B2 (en) 2003-09-23
JP2002534388A (ja) 2002-10-15
ATE293447T1 (de) 2005-05-15
CN1915981A (zh) 2007-02-21
DE60019555C5 (de) 2009-07-09
WO2000040247A8 (en) 2001-02-15
US20030027821A1 (en) 2003-02-06
WO2000040247A9 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
HK1047588B (zh) 治疗肥胖症的2-氧-4h-3,1-苯并恶嗪-4-酮
US7776853B2 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
US6916808B2 (en) 2-thio-4h-3, 1-benzoxazin-4-one derivatives for use as enzyme inhibitors
HK1103928B (en) 2-oxy-4h-3,1-benzoxazin-4-ones for treatment of obesity
TWI293953B (xx)
PL203688B1 (pl) Pochodne 2-oksy-4H-3,1-benzoksazyn-4-onu, sposób ich wytwarzania, srodek farmaceutyczny i zastosowanie pochodnych 2-oksy-4H-3,1-benzoksazyn-4-onu

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180106